Crispr Therapeutics shares tumble after significant earnings miss
HOUSTON—Jason Ingersoll, Senior Vice President of Archrock, Inc. (NYSE:AROC), has sold a significant portion of his holdings in the company. According to a recent SEC filing, Ingersoll sold 42,036 shares of common stock on May 9, 2025. The shares were sold at an average price of $24.488, totaling approximately $1.03 million. The transaction comes as Archrock, with a market capitalization of $4.54 billion, has delivered a strong 26.46% return over the past year. InvestingPro analysis indicates the stock is trading above its Fair Value, with analyst price targets ranging from $29 to $32.
The transaction was executed in multiple trades, with prices ranging from $24.27 to $24.67. Following this sale, Ingersoll retains direct ownership of 275,911 shares of Archrock. The company maintains a "GOOD" Financial Health Score according to InvestingPro, which offers comprehensive analysis through its Pro Research Report, including detailed insider trading patterns and valuation metrics.
In other recent news, Archrock Inc. reported strong financial results for the first quarter of 2025, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $0.42, exceeding the forecast of $0.39, and reported revenues of $347.2 million, which also beat the anticipated $342.59 million. The company highlighted a 35% year-over-year growth in contract operations revenue, reflecting increased demand for its services. Archrock’s financial stability was further enhanced by achieving a record low leverage ratio of 3.2x. Additionally, Archrock announced the completion of its acquisition of NGCS, which is expected to expand its operations and customer relationships. The company also raised its 2025 adjusted EBITDA guidance to a range of $790-830 million, indicating confidence in continued growth. Analysts from firms such as Raymond (NSE:RYMD) James and Citi have shown interest in Archrock’s strategic moves and market positioning. These developments suggest a focus on maintaining strong financial health and expanding market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.